Clinical trials: in Luxembourg
Hypertension, Resistant to Conventional Therapy
Rapid Renal Sympathetic Denervation for Resistant Hypertension
The Covidien OneShot™ ablation system use is to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
- Trial name
- RAPID (NCT01520506)
- Testing
- Covidien OneShot™ System
- Where
- 14 sites in Belgium, Germany and 4 more
- Volunteers
- 50 people
- Sponsor
- Medtronic Endovascular
Intractable Chronic Migraine
Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
The purpose of this study is to evaluate the long-term safety and performance of neurostimulation for the treatment of intractable chronic migraine as well as to detect infrequent complications or problems only apparent in…
- Trial name
- Relief (NCT02227758)
- Where
- 18 sites in Belgium, Germany and 4 more
- Volunteers
- 112 people
- Sponsor
- Abbott Medical Devices
Acute Myeloid Leukemia
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine improves remission rates and extends overall survival as compared to placebo…
- Trial name
- CASCADE (NCT02785900)
- Testing
- 33A, azacitidine, decitabine
- Where
- 128 sites in United States, Australia and 14 more
- Volunteers
- 240 people
- Sponsor
- Seagen Inc.
Diabetes Mellitus, Type 2, Cardiovascular Diseases
CANVAS - CANagliflozin cardioVascular Assessment Study
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE).
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
- Trial name
- CANVAS (NCT01032629)
- Testing
- Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
- Where
- 305 sites in United States, Argentina and 23 more
- Volunteers
- 4,330 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small-Cell Lung Carcinoma
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
This open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and efficacy of alectinib in participants with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment.
- Trial name
- NCT01801111
- Testing
- Erlotinib, Alectinib
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 138 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice
This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.
- Trial name
- NCT02552940
- Testing
- Tocilizumab
- Where
- 22 sites in Belgium, Luxembourg
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
Safety and Effectiveness of Regorafenib
This study is a prospective observational cohort study. The study will be conducted in routine clinical practice settings. It is planned to enroll 1000 patients with metastatic Colorectal Cancer (mCRC) who have been previously…
- Trial name
- Correlate (NCT02042144)
- Testing
- Stivarga (Regorafenib, BAY73-4506)
- Where
- 13 sites in Argentina, Austria and 11 more
- Volunteers
- 1,034 people
- Sponsor
- Bayer
Non Squamous Lung Cancer
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
- Trial name
- PROFILE 1014 (NCT01154140)
- Testing
- treatment
- Where
- 249 sites in United States, Australia and 29 more
- Volunteers
- 343 people
- Sponsor
- Pfizer
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Observational Prospective Study on Patients Treated With Norditropin®
This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®.
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Adult Growth Hormone Deficiency, Genetic Disorder
- Trial name
- NCT00960128
- Testing
- somatropin
- Where
- 23 sites in Argentina, Belgium and 21 more
- Volunteers
- 21,249 people
- Sponsor
- Novo Nordisk A/S
Rheumatoid Arthritis
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment
This open-label, single-arm study will evaluate the efficacy, safety and tolerability of subcutaneously administered tocilizumab in monotherapy and/or in combination with methotrexate and other non-biologic disease modifying…
- Trial name
- NCT02031471
- Testing
- tocilizumab
- Where
- 17 sites in Belgium, Luxembourg
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily…
- Trial name
- ADAPT (NCT00117780)
- Testing
- insulin detemir, insulin aspart
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin
This study is conducted in Europe. The objective of this observational study is to evaluate the number of serious side effects, when initiating NovoMix® treatment in patients with type 2 diabetes who previously used a human…
- Trial name
- Mix2Mix (NCT00775736)
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70
- Where
- 2 sites in Belgium, Luxembourg
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Rheumatoid Arthritis
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
This observational study will evaluate the presence and evolution of fatigue on treatment with RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis who have an inadequate response to at least…
- Trial name
- NCT01667458
- Where
- 18 sites in Belgium, Luxembourg
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis.
- Trial name
- NCT00545909
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 57 sites in Austria, Belgium and 3 more
- Volunteers
- 585 people
- Sponsor
- Hoffmann-La Roche
Aortic Valve Stenosis
Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis
The purpose of the study is to determine the safety and performance of the Direct Flow Medical study valve and delivery procedure.
- Trial name
- NCT01475799
- Testing
- Replacement of the Aortic Stenotic Valve
- Where
- 12 sites in France, Germany and 3 more
- Volunteers
- 112 people
- Sponsor
- Direct Flow Medical, Inc.
Venous Thromboembolism
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the…
- Trial name
- MAGELLAN (NCT00571649)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 676 sites in United States, Argentina and 51 more
- Volunteers
- 8,101 people
- Sponsor
- Bayer
Hepatitis C, Chronic
Telaprevir Open-Label Study in Co-Infected Patients
The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFN-alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated…
- Trial name
- NCT01500616
- Testing
- Telaprevir
- Where
- 29 sites in Belgium, Germany and 6 more
- Volunteers
- 122 people
- Sponsor
- Janssen-Cilag International NV
Neoplasms, Breast
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
- Trial name
- NCT00338247
- Testing
- lapatinib + capecitabine
- Where
- 453 sites in United States, Australia and 43 more
- Sponsor
- Novartis
Nonsquamous Nonsmall Cell Neoplasm of Lung
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC).
- Trial name
- TEAM (NCT01161173)
- Testing
- Erlotinib
- Where
- 36 sites in Belgium, Luxembourg
- Volunteers
- 347 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Lung Cancer
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
To evaluate the overall survival (OS) of patients with advanced squamous cell lung cancer receiving the combination of gemcitabine/carboplatin either with or without Iniparib.
- Trial name
- ECLIPSE (NCT01082549)
- Testing
- gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
- Where
- 142 sites in United States, Belgium and 12 more
- Volunteers
- 780 people
- Sponsor
- Sanofi